Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) COO Sells 1,198 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) COO Julianne Bruno sold 1,198 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the sale, the chief operating officer now directly owns 8,263 shares in the company, valued at approximately $350,516.46. The trade was a 12.66 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

CRISPR Therapeutics Trading Up 2.6 %

NASDAQ:CRSP traded up $1.12 on Wednesday, hitting $43.49. 1,399,700 shares of the stock were exchanged, compared to its average volume of 2,256,949. CRISPR Therapeutics AG has a fifty-two week low of $36.52 and a fifty-two week high of $76.86. The stock has a fifty day moving average of $43.02 and a 200-day moving average of $45.65. The stock has a market cap of $3.73 billion, a PE ratio of -9.95 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Institutional Investors Weigh In On CRISPR Therapeutics

Several large investors have recently added to or reduced their stakes in CRSP. Wood Tarver Financial Group LLC bought a new stake in CRISPR Therapeutics in the 4th quarter valued at about $30,000. Wilmington Savings Fund Society FSB bought a new stake in CRISPR Therapeutics during the third quarter worth approximately $40,000. Ameriflex Group Inc. bought a new position in CRISPR Therapeutics during the fourth quarter valued at about $36,000. Darwin Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics in the 3rd quarter worth approximately $43,000. Finally, Highline Wealth Partners LLC bought a new stake in shares of CRISPR Therapeutics in the 4th quarter worth approximately $39,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on CRSP shares. Morgan Stanley boosted their target price on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a report on Friday, February 14th. Stifel Nicolaus reduced their target price on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. HC Wainwright restated a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Chardan Capital dropped their target price on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Finally, Bank of America decreased their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $73.11.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.